Vaccine delivery platform
Griffith Enterprise's Griffith Institute for Drug Discovery has developed a biopolymer-based technology for producing vaccines and diagnostics in high yield and purity in bacterial cells.
Unique selling point/competitive advantage
This vaccine platform technology produces biopolymer beads decorated with covalently linked and densely packed antigens, which are highly effective in inducing immunogenicity. New vaccines can be developed and ready for use within 4–6 months. This platform is applicable for any existing and emerging pathogenic threats.
Investment or collaboration opportunities
Griffith Enterprise - Griffith Institute for Drug Discovery is seeking co-development programs to apply the vaccine platform technology to the development of new vaccine candidates.
Phone: +61 7 3735 5489
Visit Griffith Enterprise for more information.
- Last reviewed: 17 Jul 2019
- Last updated: 29 May 2018